|Individualizing Patient Care: Navigating Drug Sequencing Strategies in Relapsed/Refractory Multiple Myeloma|
Saad Z. Usmani, MD, FACP
|Release Date: October 25, 2017|
Expiration Date: October 25, 2018
A major challenge in the treatment of patients with relapsed/refractory multiple myeloma (RRMM) is the selection of therapy among a multitude of treatment options. A number of factors must be considered when sequencing drugs, including but not limited to: efficacy and tolerability of prior therapies received; performance status and organ function; cytogenetic profile and other high-risk features; and characteristics of the relapse, such as timing and aggressiveness. In this activity, participants will learn about the recommended drug sequencing strategies that will help them in choosing therapy and individualizing treatment for their patients with RRMM.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|